Quanta, a MedTech company for dialysis care, has scored a whopping $245 million in its oversubscribed and upsized Series D funding round.
Glenview Capital and Novo Holdings co-led the round. Other participating investors include BlackRock, Eldridge, Sands Capital, Millennium, Monashee Investment Management, Puhua Capital, Segulah Medical and Ancora, Orlando Health, Wellington Partners, btov, Seroba Life Sciences, and The Grands.
“Everybody knows that dialysis care must improve,” John Milad, CEO of Quanta, said in a statement. “For this to happen, providers and physicians need products that allow greater flexibility to bring dialysis directly to the patient while simplifying complexity and reducing the overall cost of care.
“Our small, simple-to-use, and powerful dialysis system SC+ is positioned to help transform kidney care. The funding we are announcing today will allow us to accelerate our emergence as a significant force in this market.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
The company plans to use the new capital to scale its global operations, specifically focusing on expanding its Beverly, Mass., facility, and growing its leadership team. It’s also preparing to begin a study of its SC+ portable hemodialysis system for in-home use after it was cleared by the FDA for use in acute and chronic care facilities.
Source: Mobihealthnews